Oxidative stress, eryptosis and anemia: a pivotal mechanistic nexus in systemic diseases
R Bissinger, AAM Bhuyan, SM Qadri… - The FEBS …, 2019 - Wiley Online Library
The average lifespan of circulating erythrocytes usually exceeds hundred days. Prior to that,
however, erythrocytes may be exposed to oxidative stress in the circulation which could …
however, erythrocytes may be exposed to oxidative stress in the circulation which could …
Reducing health care disparities in sickle cell disease: a review
LT Lee, K Smith-Whitley, S Banks… - Public Health …, 2019 - journals.sagepub.com
Sickle cell disease (SCD) is an inherited blood disorder most common among African
American and Hispanic American persons. The disease can cause substantial, long-term …
American and Hispanic American persons. The disease can cause substantial, long-term …
Genotypic and phenotypic composition of sickle cell disease in the Arab population-a systematic review
Sickle cell disease (SCD) is a genetic disease influenced by ethnicity and regional
differences in its clinical course. Recent advances in the management of SCD with newer …
differences in its clinical course. Recent advances in the management of SCD with newer …
[HTML][HTML] Surveillance for sickle cell disease—Sickle Cell Data Collection Program, two states, 2004–2018
AB Snyder - MMWR. Surveillance Summaries, 2022 - cdc.gov
Abstract Problem/Condition: Sickle cell disease (SCD), an inherited blood disorder affecting
an estimated 100,000 persons in the United States, is associated with multiple complications …
an estimated 100,000 persons in the United States, is associated with multiple complications …
Chronic pain during pregnancy: a review of the literature
SL Ray-Griffith, MP Wendel, ZN Stowe… - International journal of …, 2018 - Taylor & Francis
Background and purpose The majority of the reviews and studies on chronic pain in
pregnancy have primarily focused on the pharmacological and non-pharmacological …
pregnancy have primarily focused on the pharmacological and non-pharmacological …
Patient reports of health outcome for adults living with sickle cell disease: development and testing of the ASCQ-Me item banks
SD Keller, M Yang, MJ Treadwell, EM Werner… - Health and quality of life …, 2014 - Springer
Background Providers and patients have called for improved understanding of the health
care requirements of adults with sickle cell disease (SCD) and have identified the need for a …
care requirements of adults with sickle cell disease (SCD) and have identified the need for a …
The effect of iron chelation therapy on overall survival in sickle cell disease and β‐thalassemia: A systematic review
SK Ballas, AM Zeidan, VH Duong… - American Journal of …, 2018 - Wiley Online Library
Red blood cell transfusions have become standard of care for the prevention of life‐
threatening anemia in patients with β‐thalassemia and sickle cell disease (SCD). However …
threatening anemia in patients with β‐thalassemia and sickle cell disease (SCD). However …
Characterizing the pathogenicity of genetic variants: the consequences of context
TH Ciesielski, G Sirugo, SK Iyengar… - NPJ Genomic …, 2024 - nature.com
Beyond initial discovery of a pathogenic variant, establishing that a variant is recurrently
associated with disease is important for understanding clinical impact and disease etiology …
associated with disease is important for understanding clinical impact and disease etiology …
Pathology of sickle cell disease
JI Malowany, J Butany - Seminars in diagnostic pathology, 2012 - Elsevier
Sickle cell disease (SCD) is a hereditary chronic hemolytic anemia with numerous clinical
consequences. Intravascular sickling of red blood cells leads to multiorgan dysfunction …
consequences. Intravascular sickling of red blood cells leads to multiorgan dysfunction …
Patient‐reported experiences in voxelotor‐treated children and adults with sickle cell disease: a semistructured interview study
C Brown, M Idowu, R Drachtman… - BioMed Research …, 2023 - Wiley Online Library
Objective. Voxelotor is a first‐in‐class sickle hemoglobin–polymerization inhibitor that was
approved in 2019 by the US Food and Drug Administration for treatment of patients with …
approved in 2019 by the US Food and Drug Administration for treatment of patients with …